Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
NAMS Stock Chart & Stats
$35.80
-$0.03(-0.12%)
At close: 4:00 PM EST
$35.80
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$14.06 - $42.00
Previous CloseN/A
Volume118.30K
Average Volume (3M)876.77K
Market Cap
$4.06B
Enterprise Value$2.68B
Total Cash (Recent Filing)$702.95M
Total Debt (Recent Filing)$266.00K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 04, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding113,390,800
10 Day Avg. Volume661,486
30 Day Avg. Volume876,774
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)3.20
Price to Sales (P/S)53.22
P/FCF Ratio-15.23
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue76.05
Enterprise Value/Gross Profit76.05
Enterprise Value/Ebitda-9.30
Forecast
1Y Price Target
$48.63Price Target Upside35.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.62
Revenue Forecast (FY)$45.04M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalAnalyst highlights that BROADWAY's reported reduction in major adverse cardiovascular events and favorable effects on atherogenic biomarkers meaningfully derisk PREVAIL and support expectations for a positive cardiovascular outcomes result.
Financial RunwayAnalyst indicates that the company's cash position provides sufficient runway to fund ongoing pivotal readouts and to support a potential U.S. commercial launch if approvals are obtained.
Regulatory Progress In EuropeAnalyst notes that marketing applications for obicetrapib and its fixed‑dose combination have been accepted for review by European regulators, supporting the potential for EU approval and a planned commercial launch in 2026.
Bears Say
Investor Sentiment And Share VolatilityAmbiguity around the PREVAIL readout schedule may heighten investor uncertainty and increase share‑price volatility as market participants await a clearer timeline.
PREVAIL Timing UncertaintyManagement's plan for a midyear update on PREVAIL timing underscores uncertainty about event accrual, creating risk that the pivotal cardiovascular readout could be delayed beyond current expectations.
Regulatory And Commercial Timing RiskUncertainty about when PREVAIL will reach the required number of events could push back regulatory filings and commercial launch plans, potentially compressing the timeline for market entry.
NewAmsterdam Pharma Company News
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $42.00 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $4.06B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Mar 04, 2026 which is in 51 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Nov 05, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.219.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.4.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 113,390,800 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 4.353%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.63 (35.84% Upside)
$48.63 (35.84% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 990.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.11%
12-Months-Change
Fundamentals
Return on Equity
-39.94%
Trailing 12-Months
Asset Growth
79.06%
Trailing 12-Months
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$48.63
▲(35.84% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Soleno Therapeutics
―
Kiniksa Pharmaceuticals
―
Immunovant
―
Ownership Overview
Currently, No data available
---